Zentalis Pharmaceuticals Inc (ZNTL) Stock: What Does the Chart Say Friday?

Overall market sentiment has been down on Zentalis Pharmaceuticals Inc (ZNTL) stock lately. ZNTL receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Zentalis Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ZNTL!

See Full ZNTL Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ZNTL Stock Today?

Zentalis Pharmaceuticals Inc (ZNTL) stock is unchanged 0% while the S&P 500 is down -0.42% as of 12:16 PM on Friday, Oct 13. ZNTL is flat $0.00 from the previous closing price of $18.75 on volume of 325,187 shares. Over the past year the S&P 500 is higher by 21.09% while ZNTL is down -16.14%. ZNTL lost -$4.82 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Zentalis Pharmaceuticals Inc click here.

More About Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Click Here to get the full Stock Report for Zentalis Pharmaceuticals Inc stock.